Upstream Bio (NASDAQ:UPB) versus Organogenesis (NASDAQ:ORGO) Head to Head Survey

Organogenesis (NASDAQ:ORGO) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Valuation & Earnings

This table compares Organogenesis and Upstream Bio”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17 million	0.23	$37.03 million	($0.86)	-1.20
Upstream Bio	$2.85 million	57.46	-$143.44 million	($2.90)	-1.03

Organogenesis has higher revenue and earnings than Upstream Bio. Organogenesis is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Organogenesis has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Upstream Bio has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.

Insider & Institutional Ownership

49.6% of Organogenesis shares are held by institutional investors. 18.8% of Organogenesis shares are held by insiders. Comparatively, 16.5% of Upstream Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Organogenesis and Upstream Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organogenesis	-19.94%	-23.89%	-11.13%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Organogenesis and Upstream Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1	2	0	0	1.67
Upstream Bio	1	2	4	0	2.43

Organogenesis presently has a consensus target price of $4.33, indicating a potential upside of 320.71%. Upstream Bio has a consensus target price of $29.67, indicating a potential upside of 892.20%. Given Upstream Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Upstream Bio is more favorable than Organogenesis.

Summary

Organogenesis beats Upstream Bio on 8 of the 13 factors compared between the two stocks.

About Organogenesis

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

About Upstream Bio

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.